Stockholders Waive Jury Trials; Bylaws Amended to Shift Voting Standard

summarizeSummary

Jade Biosciences announced that stockholders approved a jury trial waiver in its Articles of Incorporation, and the Board adopted amended bylaws that include a revised voting standard for non-director elections.

check_boxKey Events · Corporate Governance and Compliance · JBIO

• Jury Trial Waiver Approved

  Stockholders approved an amendment to the Articles of Incorporation to waive jury trials for certain internal corporate claims, effective June 10, 2026. This directs such disputes to a judge, not a jury.

• Bylaws Amended with New Voting Standard

  The Board adopted amended and restated Bylaws, effective June 9, 2026. Key changes include updating the voting standard for non-director elections to require votes 'for' to exceed votes 'against', rather than a majority of votes cast.

• Routine Annual Meeting Results

  Stockholders re-elected two Class II Directors, Christopher Cain, Ph.D. and Tom Frohlich, and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis · JBIO · Life Sciences

Jade Biosciences' stockholders approved an amendment to the Articles of Incorporation to waive jury trials for certain internal corporate claims, which can significantly impact shareholder litigation by directing disputes to a judge rather than a jury. Concurrently, the Board adopted amended bylaws that change the voting standard for non-director elections, making it easier for management-backed proposals to pass by requiring votes 'for' to exceed votes 'against,' rather than a majority of all votes cast. These combined changes represent a notable shift in corporate governance, potentially reducing shareholder power and streamlining legal processes for the company.